NASDAQ · Biotechnology

Ensysce Biosciences, Inc. (ENSC) Stock

$0.46 +6.66% NASDAQ: ENSC Healthcare

Valuation

MetricValue
Price$0.46
Market Cap$7.04M
P/E Ratio-0.16
P/B Ratio-7.16
P/S Ratio5.67
EPS (TTM)$-3.98
52-Week High$2.75
52-Week Low$0.23
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-631.47%
ROA-426.88%
ROCE-500.00%
Gross Margin-72.88%
Operating Margin-4.19%
Net Margin-810.57%
Debt/Equity-0.25
Current Ratio1.59

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-20.0M$-24.0M$-11.0M$-7.0M$-10.0M
Net Profit$-29.0M$-24.0M$-11.0M$-8.0M$-10.0M
EPS$-355.68$-139.44$-4.69$-4.57$-3.98
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$16.0M$6.0M$3.0M$6.0M$7.0M
Total Liabilities$25.0M$10.0M$3.0M$2.0M$5.0M
Cash$12.0M$3.0M$1.0M$4.0M$4.0M
Borrowings$17.0M$4.0M$1.0M$0$0

Latest News

Ensysce Biosciences Receives Final $5.3 Million NIDA Funding Installment for PF614-MPAR Development InvestorsHub · Jul 14, 2026 Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant ACCESS Newswire · Jul 14, 2026 ENSC Receives Vital Funding for Drive to Commercialization Zacks Small Cap Research · Jul 14, 2026 Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth GlobeNewswire · Jul 13, 2026 Postoperative Pain - Pipeline Insight, 2026 Now Available; Comprehensive Profiles of 40+ Key Players Including Ensysce Biosciences and Allay Therapeutics GlobeNewswire · Jul 9, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-8.0M$-18.0M$-11.0M$-8.0M$-8.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$-1.0M$-1.0M$-2.0M$-1.0M
Net Cash Flow$12.0M$-9.0M$-2.0M$2.0M$1.0M
Free Cash Flow$-8.0M$-18.0M$-11.0M$-8.0M$-8.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.01
EV / EBITDA-0.49
FCF Yield-136.09%
Quick Ratio0.70
Interest Coverage-791.64
Return 1Y-86.19%
Return 3Y-99.01%
Return 5Y-100.00%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AIMAIM ImmunoTech Inc. $0.18 -1.75% -0.05 $7.04M 0.00%
CANFCan-Fite BioPharma Ltd. $3.30 -2.37% -0.74 $1.78M 0.00%
KALAKALA BIO, Inc. $0.30 -17.61% -0.01 $5.74M 0.00%
KZIAKazia Therapeutics Ltd ADR $14.54 +2.76% -2.01 $23.55M 0.00%
OGENOragenics Inc. $0.47 +2.29% -0.14 $2.14M 0.00%

About Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc. is led by CEO D. Lynn Kirkpatrick, employs 7 people, headquartered in US, publicly traded since 2018.

Ensysce Biosciences, Inc. (ENSC) stock trades at $0.46 with a market capitalization of $7.04M. The stock is valued at a price-to-earnings (P/E) ratio of -0.16, price-to-book of -7.16, price-to-sales of 5.67. Over the past 52 weeks the stock has ranged between $0.23 and $2.75, and currently trades 83.3% below its 52-week high.

On profitability, Ensysce Biosciences, Inc. generates a return on equity (ROE) of -631.47%, return on capital employed of -500.00%, an operating margin of -4.19%, a net profit margin of -810.57%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1178.88 +0.79% JNJ Johnson & Johnson $260.66 +1.63% ABBV AbbVie Inc. $277.31 +1.80% MRK Merck & Company, Inc. Common Stock (new) $145.34 +2.08% UNH UnitedHealth Group Incorporated Common Stock (DE) $376.24 +1.43% NVS Novartis AG $143.26 +0.10% AZN AstraZeneca PLC $159.80 +0.64% TMO Thermo Fisher Scientific Inc $658.31 +0.97% AMGN Amgen Inc. $413.31 +1.44% GILD Gilead Sciences, Inc. $151.18 +2.77% ABT Abbott Laboratories $99.69 +1.21% NVO Novo Nordisk A/S $38.39 +0.54%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides